FDA
The Latest
-
FDA Approves Rezdiffra, First Drug for Common and Serious Liver Disease NASH
The U.S. Food and Drug Administration (FDA) has announced the approval of Rezdiffra (resmetirom), the first drug to treat non-cirrhotic non-alcoholic steatohepatitis (NASH), a common and serious liver disease affecting millions of Americans. 
The U.S. Food and Drug Administration (FDA) has announced the approval of Rezdiffra (resmetirom), the first drug to treat non-cirrhotic non-alcoholic steatohepatitis (NASH), a common and serious liver disease affecting millions of Americans. -
FDA Holds Off on Eli Lilly's Donanemab Approval, Calls for Expert Review
The Food and Drug Administration (FDA) has opted to delay its decision on the much-anticipated Alzheimer's drug, donanemab, developed by Eli Lilly and Company. Contrary to expectations for an imminent approval, the FDA has called for a review by an independent panel of experts to delve deeper into the drug's safety and efficacy concerns. 
The Food and Drug Administration (FDA) has opted to delay its decision on the much-anticipated Alzheimer's drug, donanemab, developed by Eli Lilly and Company. Contrary to expectations for an imminent approval, the FDA has called for a review by an independent panel of experts to delve deeper into the drug's safety and efficacy concerns. -
FDA Issues Urgent Warning as Salmonella Outbreak Linked to Cantaloupes Escalates
The outbreak, which has spread across 32 states, has led to at least two deaths and numerous hospitalizations, intensifying concerns about food safety. 
The outbreak, which has spread across 32 states, has led to at least two deaths and numerous hospitalizations, intensifying concerns about food safety. -
A New Hope for Alzheimer's Treatment: FDA Approves Leqembi, Paving the Way for Insurance Coverage
The U.S. Food and Drug Administration (FDA) granted approval for Leqembi, an Alzheimer's disease drug developed by Japanese pharmaceutical company Eizai and Massachusetts-based Biogen on Thursday, July 6. 
The U.S. Food and Drug Administration (FDA) granted approval for Leqembi, an Alzheimer's disease drug developed by Japanese pharmaceutical company Eizai and Massachusetts-based Biogen on Thursday, July 6. -
U.S. FDA Permits Pharmacists To Prescribe COVID-19 Pill By Pfizer
Now, U.S. pharmacists can directly recommend the most popular COVID-19 medication to patients. 
Now, U.S. pharmacists can directly recommend the most popular COVID-19 medication to patients. -
Juul Seeks Stay Of FDA Ban On U.S. Sales Of Its E-Cigarettes
Juul said it disagrees with the FDA's decision and it will be exploring legal options. 
Juul said it disagrees with the FDA's decision and it will be exploring legal options. -
FDA Reportedly Set To Ban Juul E-cigarettes From U.S. Market
The information was released the same week that the Biden administration unveiled measures to lower the amount of nicotine in cigarettes. 
The information was released the same week that the Biden administration unveiled measures to lower the amount of nicotine in cigarettes. -
Organic Strawberries Linked To Hepatitis A Outbreak In Three U.S. States
The CDC and the FDA are investigating strawberries sold by FreshKampo and HEB in the U.S. and Canada. 
The CDC and the FDA are investigating strawberries sold by FreshKampo and HEB in the U.S. and Canada. -
Jif Peanut Butter Recall Expanded Due To Salmonella Risk
Cargill has expanded the recall to include Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways, and Peanut Butter Eggs and Fudge. 
Cargill has expanded the recall to include Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways, and Peanut Butter Eggs and Fudge. -
Family Dollar Forced To Close Down 400 Stores Due To Rat Infestation
The FDA forced Family Dollar to close down more than 400 of its locations after a rat infestation was discovered at one of its distribution facilities. 
The FDA forced Family Dollar to close down more than 400 of its locations after a rat infestation was discovered at one of its distribution facilities.
